Jeffrey William Henderson, a director at Becton Dickinson & Co (NYSE:BDX), recently acquired 1,500 shares of the company's common stock. The purchase, which took place on February 10, 2025, was made ...

According to the company, medical essentials and interventional lead the medical technology unit's business lines, bringing ...

Last week, readers were most interested in a story about BD's plan to separate its Biosciences and Diagnostics Solutions business by the end of 2026.

Citi analyst Joanne Wuensch maintained a Buy rating on Becton Dickinson (BDX – Research Report) today. The company’s shares closed last Friday ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

William Blair analyst A. Brackmann anticipates that the medical instruments supplier will post earnings of $3.34 per share for […] ...

Becton Dickinson & Co. closed 9.83% short of its 52-week high of $251.99, which the company reached on February 3rd.

Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year’s $2.68. Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...